Drug Profile
SER 140
Alternative Names: SER-140; SER-140-T2DLatest Information Update: 20 Jan 2021
Price :
$50
*
At a glance
- Originator Phlogo
- Developer Serodus
- Class Anti-inflammatories; Peptides
- Mechanism of Action Interleukin-1 beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diabetic nephropathies
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 20 Jan 2021 Discontinued - Preclinical for Type 1 diabetes mellitus in Norway (Parenteral) (Serodus' pipeline, January 2021)
- 20 Jan 2021 Preclinical trials in Diabetic nephropathies in Norway (Parenteral) before January 2021 (Serodus' pipeline, January 2021)
- 31 Dec 2019 Serodus has patent protection for SER 140 before 2019